News | May 26, 2023
Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
India’s efforts are aimed at boosting health at the last mile
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Testing supporting allergy diagnosis now accessible to more people in more communities
These initiatives aim to improve access to healthcare for rare disease patients
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
Cautions against fragmented & siloed efforts in addressing the challenges faced by the world and underlined the need for collaborative efforts to ensure global health security
Subscribe To Our Newsletter & Stay Updated
